首页> 外文期刊>RSC Advances >Designing, docking and molecular dynamics simulation studies of novel cloperastine analogues as anti-allergic agents: homology modeling and active site prediction for the human histamine H1 receptor
【24h】

Designing, docking and molecular dynamics simulation studies of novel cloperastine analogues as anti-allergic agents: homology modeling and active site prediction for the human histamine H1 receptor

机译:新型Cloperastine类似物的设计,对接与分子动力学模拟研究作为抗过敏剂:人组胺H1受体的同源性建模与活性位点预测

获取原文
获取原文并翻译 | 示例
           

摘要

The present study predicts a three-dimensional model for the histamine H1 receptor and the design of antihistamine inhibitors using cloperastine as the core molecule by docking studies. In this work, we predicted a three-dimensional structure of the histamine H1 receptor using the MODELLER9V7 software. The protein structure was developed based on the crystal structure of the histamine H1 receptor, the lysozyme chimera of Escherichia virus T4 (PDB ID: ; 3RZE_A) target collected from the PDB data bank. Using molecular dynamics simulation methods, the final predicted structure is obtained and further analyzed by VERIFY3D and PROCHECK programs, confirming that the final model is reliable. The drug derivatives of cloperastine were designed and docking was performed with the designed ligands along with the drug. The predicted model of the histamine H1 receptor structure is stable and confirms that it is a reliable structure for docking studies. The results indicate that MET 183, THR 184 and ILE 187 in the histamine H1 receptor are important determinant residues for binding as they have strong hydrogen bonding with cloperastine derivatives. The drug derivatives were docked to the histamine H1 receptor protein by hydrogen bonding interactions and these interactions played an important role in the binding studies. The molecule 1-{2-[(4-chlorophenyl) (phenyl) methoxy] ethyl}-4-methylenepiperidine showed the best docking results with the histamine H1 receptor. The docking results predicted the best compounds, which may act as better drugs than cloperastine and in the future, these may be developed for anti-allergy therapy.
机译:本研究预测组胺H1受体的三维模型和使用Cloperastine作为核心分子的抗组胺药抑制剂的设计通过对接研究。在这项工作中,我们预测了使用Modeller9v7软件的组胺H1受体的三维结构。基于组胺H1受体的晶体结构开发了蛋白质结构,从PDB数据库收集的大肠杆菌病毒T4(PDB ID:; 3RZE_A)靶标的溶菌酶嵌合体。使用分子动力学模拟方法,获得最终预测结构并通过验证3D和Procheck程序进一步分析,确认最终模型是可靠的。设计了Cloperastine的药物衍生物,并用设计的配体与药物一起进行对接。组胺H1受体结构的预测模型是稳定的并且证实它是对接研究的可靠结构。结果表明,组胺H1受体中的183,Thr 184和ILe 187是用于结合的重要决定因子残基,因为它们具有强氢键与氯氰基衍生物。通过氢键相互作用将药物衍生物对接至组胺H1受体蛋白质,这些相互作用在结合研究中起重要作用。分子1- {2- [(4-氯苯基)(苯基)甲氧基]乙基} -4-甲基哌啶显示器与组胺H1受体的最佳对接结果显示。对接结果预测了最佳化合物,其可以作为比克普利啶和未来更好的药物,这些化合物可以用于抗过敏疗法。

著录项

  • 来源
    《RSC Advances》 |2020年第8期|共10页
  • 作者单位

    JNTUA Dept Biotechnol Anantapur 515002 Andhra Pradesh India;

    Sri Venkateswara Univ Dept Microbiol Tirupati 517502 Andhra Pradesh India;

    Sri Venkateswara Univ Dept Biochem Tirupati 517502 Andhra Pradesh India;

    Sri Venkateswara Univ Dept Biochem Tirupati 517502 Andhra Pradesh India;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号